Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.

Sara Volpe Giuseppe Lisco Margherita FanelliDavide RacanielloValentina ColaianniDomenico TriggianiRossella Donghia Lucilla Crudele Roberta RinaldiCarlo SabbàTriggiani VincenzoGiovanni De PergolaGiuseppina Piazzolla

Published in: Nutrients (2022)

Besides glucose control and body composition improvements, Semaglutide was effective in ameliorating the clinical appearance and severity of NAFLD in T2D patients.

Keyphrases

body composition
end stage renal disease
resistance training
ejection fraction
newly diagnosed
peritoneal dialysis
randomized controlled trial
type diabetes
patient reported outcomes
adipose tissue
metabolic syndrome
skeletal muscle
insulin resistance
glycemic control